Arthur Bedrosian v. IRS
Case Number:
21-1583
Court:
Nature of Suit:
Government Agencies
-
September 27, 2022
Ex-Pharma CEO Denied 3rd Circ. Rehearing In $1M FBAR Case
The Third Circuit declined Tuesday to reconsider its decision backing $1 million in penalties imposed against a former pharmaceutical CEO for failing to report his Swiss bank accounts.
-
September 06, 2022
Ex-Pharma CEO Asks 3rd Circ. To Rehear $1M FBAR Case
A former pharmaceutical CEO asked the full Third Circuit on Tuesday to rethink a three-judge panel's affirmation of $1 million in penalties imposed against him for failing to report his Swiss bank accounts.
-
July 22, 2022
3rd Circ. Backs $1M FBAR Penalty Against Ex-Pharma CEO
A former pharmaceutical CEO faces almost $1 million in penalties for failing to report his Swiss bank accounts after a Third Circuit panel Friday affirmed a lower court ruling that his omission was willful.
-
March 02, 2022
3rd Circ. Looks Askance At US's Bank Evidence In FBAR Fight
A Third Circuit panel seemed wary Wednesday of the U.S. government's use of a UBS document to prove the validity of its foreign bank account reporting penalty calculation against an ex-pharmaceutical executive, saying the record's connection to him is unclear.
-
February 28, 2022
3rd Circ. Preview: March Roars With Ch. 11, Poaching Spats
The Third Circuit's March argument schedule has panels digging into arbitration matters surrounding a National Football League agent's poaching row and contract claims against a pharmacy benefit manager, as well as probing a third-party agreement that sank an overtime suit by energy inspectors.
-
November 09, 2021
US Didn't Prove FBAR Violation Was Willful, 3rd Circ. Told
The Third Circuit should overturn a lower court award of over $1 million in penalties against a former pharmaceutical CEO because the U.S. government failed to show he willfully failed to report his foreign bank accounts, he told the court.
-
October 18, 2021
Ex-Pharma CEO's FBAR Violation Was Willful, 3rd Circ. Told
The U.S. government urged the Third Circuit against revisiting a former pharmaceutical executive's dispute over $1 million in penalties for failing to report an offshore bank account, arguing that a district court correctly found his conduct was willful.